Biological targeted therapy serves as a new alternative treatment for psoriasis due to its minimal side effects. This study is aimed at examining the drug effectiveness and safety of risankizumab and ustekinumab for psoriasis treatment, so as to provide a reference for clinical decision-making. Databases from Embase, Web of Science, PubMed, and Cochrane Library were gathered, starting from inception to March 1, 2022, for randomized controlled trials regarding risankizumab and ustekinumab for psoriasis treatment. All retrieved articles were carefully selected in strict accordance with a set of inclusion and exclusion criteria. Stata 15.0 and RevMan 5.4 were applied to perform meta-analysis and risk of bias assessment. A total of two trials with three NCTs were selected, with 384 participants in the risankizumab group and 140 participants in ustekinumab. Meta-analysis showed that in the long-term and short-term PASI100, risankizumab was more effective than ustekinumab ( RR = 2.27 , 95% CI (1.77, 2.90), p < 0.05 ; RR = 2.33 , 95% CI (1.75, 3.08), p < 0.05 ). In PASI90, RR = 1.77 , 95% CI (1.54, 2.03), and p < 0.05 and RR = 1.72 , 95% CI (1.48, 2.00), and p < 0.05 . In short-term PASI75, RR = 1.23 , 95% CI (1.13, 1.34), and p < 0.05 . In sPGA of 0, the results at week-16 and week-52 showed that risankizumab was significantly more effective than ustekinumab ( RR = 2.24 , 95% CI (1.67, 3.01), p < 0.05 ; RR = 2.30 , 95% CI (1.80, 2.95), p < 0.05 ). Risankizumab was significantly more effective than ustekinumab in improving the quality of life and PSS scores ( RR = 1.48 , 95% CI (1.26, 1.75), p < 0.05 ; RR = 2.01 , 95% CI (1.41, 2.85), p < 0.05 ). Nevertheless, risankizumab and ustekinumab did not show significant difference in the incidence of adverse responses ( RR = 1.02 , 95% CI (0.75, 1.39), p > 0.05 ). Risankizumab was more effective than ustekinumab for the treatment of psoriasis. The adverse reactions of both risankizumab and ustekinumab were similar and could be tolerated. Risankizumab might be a better alternative option for their treatment.

Psoriasis is a genetic chronic disease mediated by the immune system with systemic and cutaneous manifestations that can significantly deteriorate patients' quality of life. Two-three percent of the population worldwide suffer from psoriasis and it imposes a substantial economic burden on patients. The aetiology is mainly related with genes and environmental factors. The pathophysiology of psoriasis is characterized by T cells and dendritic cells, antimicrobial peptides, genetic predispositions, lipoprotein-2, galactosin-3, fractalkine, vaspin, and human neutrophilic peptides, etc. in the progression of psoriasis. For patients with psoriasis, the traditional treatments include corticosteroids, vitamin D 3 analogues, calcineurin inhibitors, methotrexate, cyclosporine, acitretin, phototherapy, and biological agents, etc. Nanodermatology is an emerging, multidisciplinary science that is gaining increasing recognition in the treatment of psoriasis. This review provides a summary of the pathophysiology, epidemiology, clinical diagnosis, and classical pharmacotherapy of psoriasis. The review also summarizes different nanotechnology therapies for effective treatment of psoriasis.

Background: Acupuncture therapy is a method of piercing needles into acupoints to treat diseases with/ without corresponding manipulations, which could serve as a useful supplementary therapy for psoriasis. The present study aimed to outline and sum up current evidence from systematic reviews (SRs)/meta-analyses (MAs) that investigate the clinical efficacy of acupuncture on psoriasis.Methods: A comprehensive search involving eight electronic databases was conducted from the date of inception to July 2021, and grey literatures were manually searched. The research was selected according to prespecified inclusion criteria and relevant data were obtained. The methodological quality of the included SRs was scrutinized using the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2) tool. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used to appraise the reporting quality of the included SRs. Risk of Bias in Systematic Reviews (ROBIS) was selected for the evaluation of bias risk of the included SRs. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was applied to determine the quality of evidence from primary outcome measures.Results: After screening, seven SRs/MAs met the inclusion criteria, including two English and five Chinese articles. All of the SRs were published between 2015 and 2020. Based on AMSTAR-2, the quality of all SRs was rated as dangerously low. Using the PRISMA-A checklist, major reporting flaws were observed in the financial statements, protocols, and registrations of the included literature. According to the ROBIS tool, two SRs/MAs were classed as low bias risk. Using the GRADE tool, this review contained 27 outcomes, with only one being classified as high-quality evidence, seven moderate-quality evidences, and 19 as low-quality evidence. The present research results advocated acupuncture therapy as a supplementary treatment for psoriasis patients; however, the evidence should still be treated with caution due to certain limitations.Conclusions: Our overview suggests that acupuncture could be used as a complementary therapy to produce effective clinical result for psoriasis. Nonetheless, considering the poor quality of SRs/Mas that advocate these findings, studies with more rigorous design, larger populations samples and of higher quality are called for to provide stronger evidence for definitive conclusions.

Review question / Objective: This study aimed to examine the drug effectiveness a n d s a f e t y o f R i s a n k i z u m a b a n d Ustekinumab for psoriasis treatment, so as to provide a reference for clinical decisionmaking.Condition being studied: Psoriasis is a prevalent chronic inflammatory dermatosis with a high recurrence rate and is associated with abnormal autoimmunity. In 2014, WHO defined it as a chronic, noninfectious, painful, disfiguring, and disabling disease that can hardly be cured.